NMEs On The Rebound? Pace of 2006 Novel Drug Approvals Bests 2005
Executive Summary
New molecular entity and novel biologic approvals appear to be rebounding from 2005's low point, an analysis of CDER approvals in 2006 to date suggests
You may also be interested in...
NME Slump Continues: FDA Clears 18 Novel Drugs In 2006, Same As 2005
FDA's final approval tally of new molecular entities in 2006 is almost a 25-year low, despite early signs that the agency was on pace to best last year's final count of NME approvals
NME Slump Continues: FDA Clears 18 Novel Drugs In 2006, Same As 2005
FDA's final approval tally of new molecular entities in 2006 is almost a 25-year low, despite early signs that the agency was on pace to best last year's final count of NME approvals
Oncology, CNS Agents May Dominate 2006 NME Approvals; 2005 Total Is 18
The first half of 2006 could bring at least five novel oncologic approvals, including three for hematologic cancers